The stock of Acorda Therapeutics Inc (NASDAQ:ACOR) hit a new 52-week low and has $19.08 target or 9.00% below today’s $20.97 share price. The 8 months bearish chart indicates high risk for the $908.15M company. The 1-year low was reported on Sep, 30 by Barchart.com. If the $19.08 price target is reached, the company will be worth $81.73M less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 344,233 shares traded hands. Acorda Therapeutics Inc (NASDAQ:ACOR) has declined 37.47% since February 26, 2016 and is downtrending. It has underperformed by 47.90% the S&P500.
Analysts await Acorda Therapeutics Inc (NASDAQ:ACOR) to report earnings on October, 27. They expect $-0.21 earnings per share, down 290.91% or $0.32 from last year’s $0.11 per share. After $-0.13 actual earnings per share reported by Acorda Therapeutics Inc for the previous quarter, Wall Street now forecasts 61.54% negative EPS growth.
Acorda Therapeutics Inc (NASDAQ:ACOR) Ratings Coverage
Out of 2 analysts covering Acorda Therapeutics (NASDAQ:ACOR), 1 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 50% are positive. Acorda Therapeutics has been the topic of 8 analyst reports since August 25, 2015 according to StockzIntelligence Inc. The stock has “Neutral” rating given by Goldman Sachs on Wednesday, March 30. Aegis Capital maintained Acorda Therapeutics Inc (NASDAQ:ACOR) rating on Wednesday, January 6. Aegis Capital has “Buy” rating and $52 price target. The stock of Acorda Therapeutics Inc (NASDAQ:ACOR) has “Outperform” rating given on Tuesday, August 25 by Cowen & Co. Stifel Nicolaus maintained Acorda Therapeutics Inc (NASDAQ:ACOR) on Tuesday, August 25 with “Buy” rating. The stock of Acorda Therapeutics Inc (NASDAQ:ACOR) earned “Buy” rating by TheStreet on Tuesday, August 25. The firm earned “Market Perform” rating on Tuesday, September 1 by Raymond James. The stock has “Neutral” rating given by JP Morgan on Tuesday, August 25. Aegis Capital initiated the stock with “Buy” rating in Tuesday, September 1 report.
According to Zacks Investment Research, “Acorda Therapeutics is commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the central nervous system. Acorda currently markets Zanaflex Capsules for the management of spasticity. The Company’s lead product candidate, Fampridine-SR, for the improvement of walking ability in persons with multiple sclerosis. It develops therapies that restore neurological function to people with spinal cord injury, multiple sclerosis and related conditions of the nervous system.”
Insitutional Activity: The institutional sentiment decreased to 1.13 in 2016 Q2. Its down 0.28, from 1.41 in 2016Q1. The ratio worsened, as 32 funds sold all Acorda Therapeutics Inc shares owned while 45 reduced positions. 14 funds bought stakes while 73 increased positions. They now own 43.11 million shares or 7.66% less from 46.68 million shares in 2016Q1.
Schwab Charles Invest Mgmt accumulated 527,488 shares or 0.02% of the stock. Voya Invest Management Lc holds 0% of its portfolio in Acorda Therapeutics Inc (NASDAQ:ACOR) for 20,702 shares. Moreover, Price T Rowe Assocs Md has 0% invested in Acorda Therapeutics Inc (NASDAQ:ACOR) for 172,210 shares. Rothschild Asset Mgmt has 0.2% invested in the company for 435,343 shares. Hussman Strategic Advisors reported 75,000 shares or 0.29% of all its holdings. Moreover, Stifel Corporation has 0.02% invested in Acorda Therapeutics Inc (NASDAQ:ACOR) for 158,660 shares. Hightower Advisors Limited Liability Co holds 24,639 shares or 0.01% of its portfolio. Walleye Trading Limited Liability holds 0% of its portfolio in Acorda Therapeutics Inc (NASDAQ:ACOR) for 700 shares. Bank & Trust Of Montreal Can has 0% invested in the company for 72,382 shares. Us Fincl Bank De holds 142 shares or 0% of its portfolio. Tiaa Cref Investment Llc has 0% invested in the company for 173,157 shares. Los Angeles Cap Mgmt And Equity Research Inc last reported 0% of its portfolio in the stock. Gotham Asset Mgmt Limited Company holds 0.02% or 69,175 shares in its portfolio. Raymond James & last reported 0% of its portfolio in the stock. Louisiana State Employees Retirement Sys has 20,400 shares for 0.03% of their US portfolio.
Insider Transactions: Since April 19, 2016, the stock had 0 buys, and 4 sales for $213,445 net activity. $42,676 worth of Acorda Therapeutics Inc (NASDAQ:ACOR) was sold by Randall Lorin. $126,885 worth of shares were sold by Hindman Andrew A. on Friday, May 13. $13,660 worth of shares were sold by Wasman Jane on Friday, September 23. 1,086 shares with value of $30,224 were sold by RAUSCHER STEVEN M on Wednesday, June 8.
More recent Acorda Therapeutics Inc (NASDAQ:ACOR) news were published by: Seekingalpha.com which released: “Acorda Therapeutics Can Deliver Sustained Growth” on August 24, 2016. Also Fool.com published the news titled: “Why Acorda Therapeutics’ Stock Sank 22.9% in March” on April 12, 2016. Fool.com‘s news article titled: “Acorda Therapeutics’ Stock Slumped in February: Is It Now a Bargain?” with publication date: March 14, 2016 was also an interesting one.
ACOR Company Profile
Acorda Therapeutics, Inc., incorporated on March 17, 1995, is a biopharmaceutical company. The Firm is engaged in the identification, development and commercialization of therapies that restore function and recovers the lives of people with neurological disorders. The Company’s commercial products include Ampyra, Fampyra, Zanaflex Capsules and a generic version of the capsules, Zanaflex tablets and Qutenza. The Company’s research and development programs include CVT-301, Dalfampridine, Plumiaz, Neuregulin Program, Remyelinating Antibodies Program, CVT-427 and Chondroitinase Program. The Company’s Ampyra (dalfampridine) Extended Release Tablets, 10 milligrams, is used as a treatment to improve walking in patients with multiple sclerosis (MS). It also markets Zanaflex Capsules and tablets, which are short-acting drugs for the management of spasticity, and Qutenza, a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia, also known as post-shingles pain. The Company’s pipeline of neurological therapies addresses a range of disorders, including MS, Parkinson’s disease, chronic post-stroke walking deficits (PSWD), epilepsy and migraine.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.